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High blood pressure facilitates the progression of 
arteriosclerosis which increases the incidence of car-
diovascular diseases such as stroke and coronary 
heart disease. Hypertension is also a major risk factor 
for developing a cardiovascular organ damages such 
as heart failure and renal dysfunction. The population 
of elderly people is increasing and these cardiovascu-
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We compared the efficacies of 2 prescriptions, one of a medium-dose angiotensin II receptor blocker 
（ARB） with high-dose of calcium channel blocker （CCB） and another of medium-dose of ARB with medi-
um-dose of CCB and a thiazide diuretic in 22 hypertensive patients who did not achieve the target blood 
pressure level with the combination of medium-dose of ARB and medium-dose of CCB. A randomized 
crossover study was performed giving a fixed combination of 100 mg irbesartan with 10 mg amlodipine or 
a fixed-dose combination of 100 mg irbesartan with 5 mg amlodipine added by 1 mg trichlormethiazide for 
12-16 weeks each. The blood pressure measured in hospital was comparable between the high-dose CCB 
period （130/77 mmHg） and the thiazide period （130/79 mmHg）. The morning and the evening blood pres-
sures measured at home were also comparable in the high-dose of CCB and the thiazide periods, while the 
evening heart rate was higher in the thiazide period than in the high-dose CCB period. As for the labora-
tory data, hemoglobin A1c （＋0.2％, p＝0.013）, serum nonHDL cholesterol （＋12 mg/dL, p＝0.047） and 
serum uric acid （＋0.8 mg/dL, p＝0.001） were significantly higher in the thiazide period than in the high-
dose CCB period. On the other hand, urinary albumin excretion （－28.8％，p＝0.026） and estimated glo-
merular filtration rate （－5.8％，p＝0.012） were significantly lower in the thiazide period than in the high-
dose CCB period. In the combination drug therapy of hypertension, the increase of CCB dose is preferable 
in preserving renal function and in avoiding adverse effects on metabolisms of glucose, lipid and uric acid.
?????????： angiotensin II receptor blocker, calcium channel blocker, diuretic, uric acid, fixed-dose 
combination, hypertension
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lar disorders greatly impairs the activity and life 
prognosis of elderly people. Therefore, it is obvious 
how important it is to control the blood pressure to 
an optimal range and prevent the occurrence of car-
diovascular organ damages, considering that hyperten-
sion is most prevalent lifestyle-related diseases.
Among the classes of antihypertensive drugs, angio-
tensin II receptor blockers （ARB） and calcium chan-
nel blockers （CCB） are widely used because both 
drugs rarely cause adverse side effects. In addition, 
the inhibition of renin-angiotensin-aldosterone （RAA） 
system is supposedly protective against the develop-
ment of cardiovascular tissue and organ injuries 1,2）. 
On the other hand, CCB exhibit certain and potent 
hypotensive effect by dilating arterioles directly. 
Therefore, these two classes of antihypertensive 
drugs are often combined when the target blood pres-
sure is not achieved by monotherapy. However, few 
patients do not reach the target blood pressure by 
this combination and need further intensified antihy-
pertensive drug therapy. While CCB generally lower 
blood pressure dose-dependently by dilating arteri-
oles, the hypotensive effects of renin-angiotensin sys-
tem inhibitors （RASI） such as angiotensin-converting 
enzyme （ACE） inhibitors and ARB depend on the 
intrinsic activity of RAA system to a greater or lesser 
extent, and the increase in drug dose do not necessar-
ily yields corresponding blood pressure reduction. 
Therefore, increasing the dose of CCB is supposedly 
preferable to intensify the hypotensive effect when 
ARB and CCB are combined. Otherwise, the addition 
of other classes of antihypertensive drugs with differ-
ent hypotensive mechanism should be considered to 
achieve effective blood pressure reduction. Especially, 
the addition of diuretics is expected to synergistically 
enhance the hypotensive effects of RASI 3）.
In the present study, we compared the therapeutic 
effects of combination antihypertensive therapy 
including high-dose of CCB or a thiazide diuretic in 
hypertensive patients requiring multiple antihyperten-
sive drugs for adequate blood pressure control.
???????
There were 22 hypertensive subjects enrolled in 
this study whose blood pressure did not achieve the 
target level by taking fixed-dose combination of medi-
um-dose of ARB （irbesartan 100 mg） and medium-
dose of CCB （amlodipine 5 mg） for three months or 
more. The target blood pressure was ＜130/80 mmHg 
for patients with diabetes mellitus or chronic kidney 
disease and ＜140/90 mmHg for other patients. 
Patients whose serum creatinine was 2.0 mg/dL or 
higher were not included because thiazide diuretics 
are contraindicated to these patients. We also exclud-
ed patients with severe hypertension exceeding 
180/110 mmHg or secondary causes of hypertension 
other than stage 1-3 chronic kidney disease. The 
background characteristics of study subjects are 
shown in Table 1. Three patients with diabetes melli-
tus were given antidiabetic drugs such as biguanides 
（n＝2）, a-glucosidase inhibitors （n＝1） and glinides 
（n＝1）. Lipid-lowering drugs （statins） and antihyper-
uricemic drugs （allopurinol and febuxostat） were 
given to seven and three patients, respectively. In 
addition, six patients were taking antiplatelet drugs 
such as aspirin. The doses of these drugs were 
unchanged throughout the study.
The patients had been given fixed-dose combina-
tion of 100 mg irbesartan and 5 mg amlodipine. Which 
was changed to fixed-dose combination of 100 mg 
irbesartan and 10 mg amlodipine, or added 1 mg of tri-
chlormethiazide. Each regimen was taken once daily 
after breakfast for 12-16 weeks, according to a ran-
domized crossover design. The sequence of treatment 
periods with high-dose of CCB and thiazide combina-
tion therapy was randomized. In hospital blood pres-
sure was measured with a sphygmomanometer in the 
???????　Baseline characteristics of the study subjects
Age, years 62.7±12.5
Gender, male/female 12/10
Body mass index, kg/m2 27.7±5.0
Systolic blood pressure, mmHg 147.2±6.8 
Diastolic blood pressure, mmHg 86.2±8.6
Heart rate, bpm 73.2±11.9
Duration of hypertension, years 13.0±8.1
Complications
　Chronic kidney disease 9 （41％） 
　Diabetes mellitus 3 （14％） 
　Dyslipidemia 8 （36％） 
　Hyperuricemia 7 （32％） 
　Cardiovascular disease 2 （9％）
Data are the mean±SD.
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sitting position after resting for at least 20 min at each 
visit every 4 weeks. Blood pressure at home was mea-
sured consecutively for 7 days before each visit using 
an arm-cuff oscillometric automatic manometer within 
1 hour of awakening （before drug administration） as 
morning blood pressure and before going to bed as 
evening blood pressure, and the mean values were 
obtained. The patients used their own manometers 
equipped with arm cuffs.
After overnight, fasting blood samples were collect-
ed in the sitting position after resting for more than 
20 minutes on the final day of each treatment period. 
In addition to the routine blood chemistry and blood 
cell counts, plasma B-type natriuretic peptide （BNP） 
was assayed using chemiluminescent enzyme immu-
noassay. The estimated glomerular filtration rate 
（eGFR） was calculated from the serum creatinine 
level and age by the following equation 4）：eGFR＝194
×Age－0.287×sCr－1.094（×0.739 for females）. Urine 
samples were collected on the final day of each treat-
ment period. Urinary albumin was measured by an 
immunoturbidimetric method and corrected using the 
urinary creatinine level.
The study protocol was in accordance with the rec-
ommendations of the World Medical Association for 
biomedical research involving human subjects and 
was approved by the institutional review board. 
Informed consent was obtained from all subjects after 
explaining the study objective and design.
Clinical data were expressed as means±standard 
deviations （SD）. Values between the 2 periods were 
compared by paired t-test, however, Wilcoxon signed-
rank test was applied for the data with skewed distri-
bution. A P value of less than 0.05 was considered to 
be statistically significant.
???????
All the 22 patients showed good adherence to the 
therapy and fulfilled the whole study periods. Table 2 
shows the in hospital blood pressure and heart rate at 
the ends of high-dose of CCB and thiazide combina-
tion therapy periods. Body weight was not significant-
ly different between the two treatment periods. There 
were no significant differences in blood pressure and 
heart rate between the two treatments periods. As 
compared with the baseline period treated by fixed 
combination of medium-dose of ARB and medium-
dose of CCB. The increased CCB dose and the thia-
zide addition comparably lowered blood pressure by 
－17/－9 mmHg and －17/－8 mmHg, respectively, 
without affecting the heart rate. Significant difference 
was not observed in the heart rate between the two 
treatment periods. Figure 1 shows at home blood 
pressure in the morning and the evening. Similar to 
the blood pressure measure in hospital, the blood 
pressure measured at home in the morning and the 
evening did not have significant difference between 
the two treatment periods. However, the heart rate in 
the evening was significantly higher in the thiazide 
period than in the high-dose CCB period.
Table 3 shows the laboratory data examined at the 
end of each treatment period. Among the hematologi-
cal parameters, hematocrit was slightly higher in the 
thiazide period than in the high-dose CCB period. 
Among the blood chemistry data, the serum levels of 
urea nitrogen, creatinine and uric acid were signifi-
cantly higher in the thiazide period than in the high-
dose CCB period. Serum K was not significantly differ-
ent between the two treatment periods. Although the 
plasma glucose and serum high-density lipoprotein 
???????　 In hospital blood pressure, heart rate and body weight at the 
ends of high-dose CCB and thiazide combination periods.
Variable High-dose CCB Thiazide P value
SBP, mmHg 130.1±12.4 129.8±11.6 0.807
DBP, mmHg 77.4±9.8 78.7±10.2 0.164
Heart rate, bpm 73.8±13.0 74.5±12.7 0.457
Body weight, kg 71.0±14.2 70.7±14.6 0.346
Data are the mean±SD. CCB：calcium channel blocker, SBP：systolic 
blood pressure, DBP：diastolic blood pressure.
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（HDL） cholesterol were not significantly different 
between the two periods, hemoglobin A1c and serum 
nonHDL-cholesterol were higher in the thiazide peri-
od than in the high-dose CCB period. Plasma BNP, 
which is supposed to reflect cardiac ventricular stress, 
was not significantly different between the two treat-
ment periods.
The eGFR and the urinary albumin excretion of the 
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????????　 Average home blood pressure and heart rate during the last week of the 
high-dose CCB period and the thiazide combination period. Data are mean±
SD. CCB：calcium channel blocker.
???????　 Laboratory data at the ends of high-dose CCB and thiazide 
combination periods.
Variable High-dose CCB Thiazide P value
Blood cell counts
White blood cell, ×103/mm3 6.81±1.96 6.79±1.69 0.997
Red blood cells, ×106/mm3 4.48±0.59 4.55±0.58 0.093
Blood hemoglobin, g/dL 13.8±1.5 14.0±1.5 0.189
Hematocrit,％ 41.6±4.5 42.6±4.2 0.027
Platelet, ×103/mm3 239±54 253±58 0.085
Blood chemistry
Aspartate transaminase, U/L 24±12 25±15 0.601
Alanine transaminase, U/L 28±25 29±27 0.625
Total protein, g/dL 7.1±0.3 7.1±0.4 0.657
Albumin, g/dL 4.2±0.3 4.2±0.4 0.930
Na, mEq/L 142±1 141±2 0.208
K, mEq/L 4.2±0.4 4.2±0.3 0.999
Urea nitrogen, mg/dL 15.8±5.1 17.6±4.8 0.021
Creatinine, mg/dL 0.92±0.29 0.97±0.27 0.020
Uric acid, mg/dL 5.8±1.6 6.6±1.5 0.001
HDL-cholesterol, mg/dL 53±14 52±13 0.590
nonHDL-cholesterol, mg/dL 135±23 147±34 0.047
Hemoglobin A1c （NGSP）, ％ 5.8±0.6 6.0±0.7 0.012
Plasma glucose, mg/dL 113±17 117±27 0.374
Plasma BNP, pg/mL 24.2±20.8 23.4±19.4 0.725
Data are the mean±SD. CCB：calcium channel blocker, HDL：high-den-
sity lipoprotein, NGSP：National Glycohemoglobin Standardization 
Program, BNP：B-type natriuretic peptide.
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study subjects at the end of each treatment period 
were depicted in Figure 2. The eGFR was higher in 
the high-dose CCB period than in the thiazide period, 
while the urinary albumin excretion was lower in the 
thiazide period than in the high-dose CCB period.
??????????
The blood pressure level of 140/90 mmHg or higher 
is generally recognized as hypertension. The latest 
versions of guidelines for the management of hyper-
tension recommend the target blood pressure to be 
lower than this 5〜7）. In addition, high-risk hypertensive 
patients complicated by diabetes mellitus or CKD pre-
senting proteinuria are recommended to lower their 
blood pressure ＜130/80 mmHg in order to prevent 
cardiovascular events and renal failure. However, 
there is not an apparent threshold level from which 
higher blood pressure is associated with the increase 
in cardiovascular diseases. Meta-analyses of prospec-
tive observational studies have indicated that there is 
a linear relationship between blood pressure and the 
risk of cardiovascular diseases such as stroke and 
myocardial infarction 8）. This relationship also exists 
even in the normal blood pressure range below 
140/90 mmHg down to 115/75 mmHg. Moreover, in 
the recent Systolic Blood Pressure Intervention Trial 
（SPRINT）, the intensive treatment hypertensive 
patients with target SBP less than 120 mmHg showed 
lower rates of cardiovascular events and death than 
in the standard treatment group targeted less than 
140 mmHg9）. Therefore, stricter target blood pressure 
level such as 130/85 mmHg may be preferable in 
order to achieve better prevention of cardiovascular 
diseases in hypertensive patients. In the real world 
clinical practice, however, generally half of the hyper-
tensive patients under antihypertensive treatment do 
not achieve even the target blood pressure level of 
140/90 mmHg. For that reason intensification of anti-
hypertensive drug therapy such as increasing the 
dose and combination of multiple agents is needed.
In the present study, we enrolled hypertensive 
patients who did not reach target blood pressure level 
by the combination of medium-doses of ARB and 
CCB, and compared the therapeutic effects of 
increased dose of CCB or an addition of thiazide 
diuretic as the next step to achieve target blood pres-
sure. Consequently, blood pressure in hospital was 
comparably lowered in either treatment period. In 
addition, also the morning and evening blood pressure 
at home did not significantly differ between the two 
treatment periods. Therefore, the high-dose of CCB 
and thiazide diuretic addition are thought to bring 
about comparable duration of antihypertensive effects. 
Amlodipine used in this study is a long-acting CCB 
with plasma half-life of more than 24 hours and has 
been shown to be effective in lowering blood pressure 
over 24 hours 10〜12）. The addition of diuretic has been 
also shown to elongate the hypotensive effects of 
????????　 Estimated glomerular filtration rate （eGFR, left panel） and urinary albumin 
excretion （right panel） at the ends of high-dose CCB and thiazide combination 
periods. Data are mean±SD. CCB：calcium channel blocker.
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other antihypertensive drugs by reducing the necessi-
ty to maintain high blood pressure level to excrete Na 
during nighttime and changing the non-dipper pat-
tern into dipper 13）. In other words, diuretics are 
thought to correct inappropriate renal excretion of Na 
which contributes to the non-dipping pattern of blood 
pressure change.
Even if the in hospital blood pressure is controlled 
in normal range, diurnal blood pressure changes such 
as morning surge and the lack of nocturnal dipping 
are known to raise the risk of cardiovascular organ 
injuries 14,15）. In this context, out of hospital blood pres-
sure values obtained by ambulatory blood pressure 
monitoring （ABPM） or blood pressure measurement 
at home have been shown to yield better prediction 
than that of the blood pressure in hospital for the inci-
dence of target organ damages and cardiovascular 
diseases 16〜18）. Therefore, the long duration of antihy-
pertensive effect yielded by high-dose of long-acting 
CCB or thiazide addition is expected to be beneficial 
in preventing cardiovascular complications and 
improving the prognosis of hypertensive patients.
With regard to the heart rate, the evening heart 
rate was higher in the thiazide period than in the 
high-dose CCB period, although the heart rate in hos-
pital did not differ between the two periods. It is spec-
ulated that the reduction in blood volume by diuresis 
may have resulted in the sympathetic nerve activa-
tion. Considering that the chronic activation of sympa-
thetic nerve system and the increase in heart rate 
have been shown to be associated with the increased 
risk of cardiovascular diseases 19,20）, thus the use of 
high-dose of CCB may be preferable to the addition 
of diuretic in the combination antihypertensive drug 
therapy aiming to improve the prognosis of hyperten-
sive patients.
Two drugs or more are often required in order to 
achieve the target blood pressure. In the combination 
drug therapy of hypertension, addition of diuretics is 
effective in reinforcing the hypotensive effects of other 
vasodilating drugs. However, the long-term use of thi-
azide diuretics often causes unfavorable side effects 
such as hypokalemia, hyperuricemia, hyperglycemia 
and dyslipidemia. In this respect, the combination of 
RASI is expected to exert opposite influences on the 
metabolism of K, glucose and lipids thereby cancel the 
adverse effects of diuretics to some degree 21,22）. Espe-
cially, in vitro studies have indicated that irbesartan 
activates peroxisome proliferator-activated receptor-
gamma （PPAR-g）, a transcription factor of nuclear 
hormone receptor, which has actions such as improv-
ing insulin resistance and reducing inflammatory cyto-
kines 23）. In the present study, serum K did not differ 
between the high-dose CCB and the thiazide periods, 
however, hemoglobin A1c, nonHDL-cholesterol and 
uric acid were higher in the thiazide period than in 
the high-dose CCB period. Therefore, the effects of 
irbesartan supposedly was not potent enough to 
negate the adverse effects of trichlormethiazide on 
glucose and lipid metabolism. RASI are generally neu-
tral as for the production and excretion of uric acid, 
however, irbesartan has been shown to facilitate uric 
acid excretion by inhibiting URAT-1, a transporter of 
uric acid reabsorption in the renal tubules and reduce 
serum uric acid 24,25）. However, this effect of irbesartan 
seems modest in clinical practice, considering that the 
serum uric acid was significantly higher in the thia-
zide period than in the high-doseCCB period in the 
present study.
In the long-term treatment of hypertension, not 
only lowering blood pressure but also reducing pro-
teinuria or albuminuria is associated with prevention 
of organ injuries and cardiovascular events, thereby 
improving the prognosis 26）. On the other hand, it has 
been also shown that the incidence of cardiovascular 
events increased in patients whose renal function had 
decreased during antihypertensive therapy 27）. Howev-
er, in the antihypertensive drug therapy, the reduc-
tion of proteinuria is not necessarily associated with 
the preservation of renal function. It is assumed that 
the increased intraglomerular capillary pressure, glo-
merular hypertension, promotes glomerulosclerosis 
and renal dysfunction. The decrease in intraglomeru-
lar capillary pressure is expected to reduce protein-
uria on the one hand, but may also reduce GFR on 
the other hand. In this respect, eGFR was favorably 
maintained by CCB compared with diuretics in the 
INSIGHT study 28,29）. The ACCOMPLISH study com-
pared the therapeutic effects of combination therapy 
with an ACE inhibitor plus diuretic and the combina-
tion of an ACE inhibitor plus CCB in high-risk hyper-
tensive patients. As for the indices of renal injury, the 
Combination antihypertensive therapy??（3）（2017） 215
CCB combination was less effective in reducing uri-
nary albumin but better preserved eGFR than the 
diuretic combination 30,31）, which is in accordance with 
the results of this study. In the ACCOMPLISH study, 
the hard endpoints such as doubling of serum creati-
nine and cardiovascular events were fewer in the 
CCB combination than in the diuretic combination. 
Thus, it may be surmised that the combination of 
RASI with CCB is preferable to the combination of 
RASI with diuretic in terms of improving the long-
term prognosis. However, considering that the contin-
uation of albuminuria and high GFR may be associat-
ed with glomerular hypertension, further follow-up 
seems to be needed for the evaluation of long-term 
renoprotective effects by antihypertensive drug thera-
py.
In summary, we compared the therapeutic effects of 
antihypertensive therapies using high-dose of CCB or 
adding thiazide diuretic in patients with insufficient 
blood pressure control with the fixed-dose combina-
tion of medium-dose of ARB and medium-dose of 
CCB. Both combination therapies comparably lowered 
blood pressure, however, the addition of thiazide was 
more likely to cause sympathetic nerve activation and 
unfavorable influences on the metabolism of glucose, 
lipids and uric acid than the high-dose of CCB combi-
nation. In the combination drug therapy of hyperten-
sion including RASI, it is suggested that the increase 
of CCB dose has advantages over the addition of thia-
zide diuretic in improving the long-term prognosis by 
avoiding adverse effects of antihypertensive drugs.
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